Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights

Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINE program- -Reported positive preclinical data at SITC demonstrating the potential to drive targeted anti-tumor immune responses with IL-2, IL-12 and IFNα